The genetic medicine revolution is underway. Just 18 months ago, very few people in the general population had heard of mRNA vaccines; now, hundreds of millions globally have been vaccinated with one.
Are plasmid DNA issues impacting your mRNA program delivery? Many biotech and pharma companies focused on advanced therapy manufacturing are experiencing challenges associated with their pDNA supply, ...
Feasibility study of a personalized tumor membrane vesicle vaccine immunotherapy for head and neck squamous cell carcinoma (HNSCC). This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I ...
Molecular cloning relies on two key components to construct recombinant DNA: 1) a DNA vector and 2) one or more DNA fragments containing the gene(s) of interest (GOI). To produce a GOI fragment, DNA ...
Every dog has its day, and Monday was Curia’s as the CDMO got its paws on a new drug manufacturing platform. Curia has enlisted enzymatic DNA production outfit Touchlight to furnish its clients with ...
What Are AAV Vector-Based Therapies? Gene therapies are groundbreaking approaches utilizing viral and non-viral vectors. These vectors introduce therapeutic genes into patient cells to treat diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results